BIRC6-ALK, a novel fusion gene in ALK break-apart FISH-negative lung adenocarcinoma, responds to crizotinib

Journal of Thoracic Oncology

Volumn 10, Issue 6, 2015, Pages e37-e39

  Shan, Ling ^a   Jiang, Peidi ^a   Xu, Feng ^a   Zhang, Weilong ^a   Guo, Lei ^a   Wu, Jian ^b   Zeng, Yixin ^c,d   Jiao, Yuchen ^a   Ying, Jianming ^a  

^a CANCER HOSPITAL   (China)

^b MyGenostics Inc   (United States)

^c PEKING UNION MEDICAL COLLEGE   (China)

^d SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CRIZOTINIB; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; BIRC6 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ADULT; ARTICLE; BIRC6 ALK FUSION GENE; CANCER CHEMOTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG RESPONSE; EXON; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; INTRON; LUNG ADENOCARCINOMA; LYMPH NODE BIOPSY; LYMPHADENOPATHY; MIDDLE AGED; PRIORITY JOURNAL; SEQUENCE ANALYSIS; ADENOCARCINOMA; GENE FUSION; GENETICS; LUNG NEOPLASMS; METABOLISM; PROCEDURES;

ADENOCARCINOMA; FEMALE; GENE FUSION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INHIBITOR OF APOPTOSIS PROTEINS; LUNG NEOPLASMS; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84938270856     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000467     Document Type: Article

References (4)

1. Peled N, Palmer G, Hirsch FR, Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib-sensitive ALK rearrangement in a patient with metastatic non-small-cell lung cancer. J Thorac Oncol 2012 7 e14 e16
2. Yoshida A, Tsuta K, Nitta H, Bright-field dual-color chromogenic in situ hybridization for diagnosing echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-positive lung adenocarcinomas. J Thorac Oncol 2011 6 1677 1686
3. Camidge DR, Kono SA, Flacco A, Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin Cancer Res 2010 16 5581 5590
4. Ren S, Hirsch FR, Varella-Garcia M, Atypical negative ALK break-apart FISH harboring a crizotinib-responsive ALK rearrangement in non-small-cell lung cancer. J Thorac Oncol 2014 9 e21 e23